
## Jose Morais

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2397890/publications.pdf Version: 2024-02-01



LOSE MODALS

#	Article	IF	CITATIONS
1	Intestinal drug transporters: An overview. Advanced Drug Delivery Reviews, 2013, 65, 1340-1356.	6.6	265
2	Imidazolidin-4-one Derivatives of Primaquine as Novel Transmission-Blocking Antimalarials. Journal of Medicinal Chemistry, 2005, 48, 888-892.	2.9	78
3	Synthesis of imidazolidin-4-one and 1H-imidazo[2,1-a]isoindole-2,5(3H,9bH)-dione derivatives of primaquine: scope and limitations. Tetrahedron, 2004, 60, 5551-5562.	1.0	68
4	Structure and rheology of semisolid o/w creams containing cetyl alcohol/non-ionic surfactant mixed emulsifier and different polymers. International Journal of Cosmetic Science, 2004, 26, 47-59.	1.2	66
5	Prediction of the human oral bioavailability by using in vitro and in silico drug related parameters in a physiologically based absorption model. International Journal of Pharmaceutics, 2012, 429, 84-98.	2.6	64
6	Developments in the rat adjuvant arthritis model and its use in therapeutic evaluation of novel non-invasive treatment by SOD in Transfersomes. Journal of Controlled Release, 2005, 103, 419-434.	4.8	62
7	Developing and advancing dry powder inhalation towards enhanced therapeutics. European Journal of Pharmaceutical Sciences, 2013, 48, 181-194.	1.9	59
8	The New European Medicines Agency Guideline on the Investigation of Bioequivalence. Basic and Clinical Pharmacology and Toxicology, 2010, 106, 221-225.	1.2	55
9	Simple high-performance liquid chromatographic assay for the determination of ciprofloxacin in human plasma with ultraviolet detection. Biomedical Applications, 2001, 755, 305-309.	1.7	54
10	Analysis of cocaine and nicotine metabolites in wastewater by liquid chromatography–tandem mass spectrometry. Cross abuse index patterns on a major community. Science of the Total Environment, 2014, 487, 673-680.	3.9	53
11	Prediction of the in vitro permeability determined in Caco-2 cells by using artificial neural networks. European Journal of Pharmaceutical Sciences, 2010, 41, 107-117.	1.9	49
12	Prediction of the in vitro intrinsic clearance determined in suspensions of human hepatocytes by using artificial neural networks. European Journal of Pharmaceutical Sciences, 2010, 39, 310-321.	1.9	47
13	Prediction of drug distribution within blood. European Journal of Pharmaceutical Sciences, 2009, 36, 544-554.	1.9	41
14	Evaluation of dissolution profile similarity – Comparison between the f2, the multivariate statistical distance and the f2 bootstrapping methods. European Journal of Pharmaceutics and Biopharmaceutics, 2017, 112, 67-74.	2.0	34
15	Determination of the antidepressant fluoxetine in human plasma by LC with UV detection. Journal of Pharmaceutical and Biomedical Analysis, 2000, 23, 989-996.	1.4	33
16	Liposomal formulations of Cu,Zn-superoxide dismutase: physico-chemical characterization and activity assessment in an inflammation model. Journal of Controlled Release, 1997, 43, 1-8.	4.8	30
17	Reactivity of imidazolidin-4-one derivatives of primaquine: implications for prodrug design. Tetrahedron, 2006, 62, 9883-9891.	1.0	28
18	Influence of the interval between the administration of doxorubicin and paclitaxel on the pharmacokinetics of these drugs in patients with locally advanced breast cancer. Cancer Chemotherapy and Pharmacology, 2001, 48, 333-337.	1.1	24

JOSE MORAIS

#	Article	IF	CITATIONS
19	An isocratic LC method for the simultaneous determination of vitamins A, C, E and β-carotene. Journal of Pharmaceutical and Biomedical Analysis, 1999, 21, 399-406.	1.4	23
20	Dipeptide Derivatives of AZT: Synthesis, Chemical Stability, Activation in Human Plasma, hPEPT1 Affinity, and Antiviral Activity. ChemMedChem, 2008, 3, 970-978.	1.6	18
21	Trifluralin liposomal formulations active against Leishmania donovani infections. European Journal of Pharmaceutics and Biopharmaceutics, 2009, 71, 292-296.	2.0	18
22	Harmonization of Regulatory Approaches for Evaluating Therapeutic Equivalence and Interchangeability of Multisource Drug Products: Workshop summary report. European Journal of Pharmaceutical Sciences, 2011, 44, 506-513.	1.9	17
23	Determination of apovincaminic acid in human plasma by high-performance liquid chromatography. Journal of Pharmaceutical and Biomedical Analysis, 1996, 14, 617-622.	1.4	14
24	Sinus Tissue Concentration of Moxifloxacin after a Single Oral Dose. Annals of Otology, Rhinology and Laryngology, 2004, 113, 142-146.	0.6	14
25	Prediction of Drug Distribution in Rat and Humans Using an Artificial Neural Networks Ensemble and a PBPK Model. Pharmaceutical Research, 2014, 31, 3313-3322.	1.7	12
26	Insights into solute carriers: physiological functions and implications in disease and pharmacokinetics. MedChemComm, 2016, 7, 1462-1478.	3.5	12
27	Sensitive method for the determination of phenytoin in plasma, and phenytoin and 5-(4-hydroxyphenyl)-5-phenylhydantoin in urine by high-performance liquid chromatography. Journal of Pharmaceutical and Biomedical Analysis, 1992, 10, 1001-1006.	1.4	9
28	An alternative single dose parameter to avoid the need for steady-state studies on oral extended-release drug products. European Journal of Pharmaceutics and Biopharmaceutics, 2012, 80, 410-417.	2.0	8
29	Population Approach to Efavirenz Therapy. Journal of Pharmaceutical Sciences, 2017, 106, 3161-3166.	1.6	8
30	Tissue-to-blood distribution coefficients in the rat: Utility for estimation of the volume of distribution in man. European Journal of Pharmaceutical Sciences, 2013, 50, 526-543.	1.9	7
31	Steroid metabolism in isolated rat hepatocytes. European Journal of Drug Metabolism and Pharmacokinetics, 1985, 10, 295-307.	0.6	5
32	A proposed approach for the determination of the bioequivalence acceptance range for narrow therapeutic index drugs in the European Union. Clinical Pharmacology and Therapeutics, 2021, 111, 470.	2.3	4
33	Absorption of intra-bronchial diprophylline-methodology and preliminary results. European Journal of Drug Metabolism and Pharmacokinetics, 1992, 17, 187-193.	0.6	3
34	Comparative bioavailability of two immediate release tablets of cisapride in healthy volunteers. European Journal of Drug Metabolism and Pharmacokinetics, 1998, 23, 377-381.	0.6	3
35	Automated flow-injection system for extending the linear range. Analytica Chimica Acta, 1998, 366, 271-279.	2.6	2
36	Effect of P-Glycoprotein on the Rat Intestinal Permeability and Metabolism of the BDDCS Class 1 Drug Verapamil. Molecular Pharmaceutics, 2013, 10, 4038-4045.	2.3	2

JOSE MORAIS

#	Article	IF	CITATIONS
37	A comparative bioavailability study to estimate the influence of an antacid on droxicam pharmacokinetics. European Journal of Drug Metabolism and Pharmacokinetics, 1995, 20, 275-279.	0.6	1
38	The utility of in vitro trials that use Caco-2 cell systems as a replacement for animal intestinal permeability and human bioequivalence measurements in drug development. Biomedical and Biopharmaceutical Research, 2015, 12, 117-126.	0.0	1
39	Synthesis of Imidazolidin-4-one and 1H-Imidazo[2,1-a]isoindole-2,5(3H,9bH)-dione Derivatives of Primaquine: Scope and Limitations ChemInform, 2004, 35, no.	0.1	0
40	Correlation between cell- and tissue-based in vitro models forÂdrug permeability screening with in vivo situation. , 2016, , 357-371.		0